-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1485 Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Yuyu Liu1*, Guanchen Bai2*, Xingli Zhao3*, Xiaohui Suo4*, Yanliang Bai, MD5*, Weihua Zhao, MD6*, Hongling Peng, MD7*, Fang Zheng8*, Dongmei Wang9*, Liyun Zhao10*, Jie Liu11, Ling Li12*, Xinxiao Lu3*, Congcong Zhang13*, Zeyan Shi14*, Yunya Luo15*, Xuemei Zhao8*, Yaxian Tan16*, ZePing Zhou, MD, PhD16, Pengxiang Guo17*, Yingchang Mi, MD18 and Kaiqi Liu18*

1Department of Hematology, The Affiliated Tai'an City Central Hospital of Qingdao University, Taian, Shandong, China, 271000, Taian, China
2Department of Hematology, The Affiliated Tai'an City Central Hospital of Qingdao University, Taian, Shandong, China, 271000., Taian, China
3Department of Hematology, Oncology Center, Tianjin People's Hospital, No. 190 jieyuan Road, Hongqiao District, Tianjin 300121, P R China., Tianjin, China
4Department of Hematology, Handan Central Hospital, Handan, Hebei, China., Handan, China
5Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, China
6Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China., Nanning, China
7Department of hematology, The second xiangya hospital of Central South University, Changsha, China
8Department of Hematology, The Second People’s Hospital of Guiyang, Guiyang, Guizhou, China, 550081., Guiyang, China
9Department of Hematology, Harrison International peace Hospital, Hengshui, Hebei, China, 053000., Hengshui, China
10Department of Hematology, People Hospital of XingTai, Xing Tai, Hebei, China, 054001, Xingtai, China
11Department of Hematology, Sinopharm Tongmei General Hospital, Datong, Shanxi, China, 037003, Datong, China
12Department of Hematology, Inner Mongolia People's Hospital, Huhehaote, Neimenggu, China, 010000, Huhehaote, China
13Department of Hematology, Handan Central Hospital, Handan, Hebei, China, 056000,, Handan, China
14Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
15Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China., Changsha, China
16Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, Kunming, China
17Department of Hematology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, China, Guiyang, China
18National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China

Background

The FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is found in approximately 20-25% of newly diagnosed acute myeloid leukemia (AML), which are previously associated with a poor prognosis. The complete response (CR) rate with conventional chemotherapy is around 50-70%. The overall survival (OS) of patients have been improved through the synergistic application of small molecule FIT3 inhibitors (sorafenib, midostaurin, quizartinib, etc) and Allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Nevertheless, no substantial enhancement in the CR rate was observed when compared to traditional chemotherapy. Venetoclax (Ven), an oral Bcl-2 inhibitor, combined with intensive chemotherapy (IC) improved CR rate in de novo AML patients. To date, there has been no reported evidence of the effectiveness of VEN combined with IC for de novo AML with FLT3/ITD.

In this study, we conducted a retrospective analysis of data from 63 newly diagnosed FLT3-ITD positive AML patients who received VEN+IC as inducion chemotherapy. The purpose of this study was to evaluate the efficacy and safety of the regimen in newly diagnosed AML with FLT3/ITD.

Methods

Retrospectively collected and analyzed the clinical data of 63 newly diagnosed AML with FLT3/ITD patients who treated with Ven combined with IC (VEN+DA: ChiCTR2200061524; VEN+HAA: ChiNCT05893472; VEN+HAD) as induction therapy between January, 2022, and June, 2024 in china.

The induction regimen consisted of a 7-day oral administration of VEN, in combination with either DA (DNR 60 mg/m²/day d2–3, and Ara-c 100 mg/m²/q12h d2–7), HAA (HHT 2.5mg/m2/day d3-7, Ara-c 100 mg/m²/day d3-7, and Acla 20mg/day d3-7), or HAD regimen (HHT 2mg/m2/day d2-6, DNR 45 mg/m²/day d 4-5, and Ara-c 100 mg/m²/day d2-6).

After achieving CR or CRi, Allo-HSCT were recommended according to ELN guideline and Chinese guidelines for the diagnosis and treatment of adult AML. Patients who cannot not proceed Allo-HSCT received consolidation and maintenance therapy.

The primary purpose was evaluated the efficacy and safety of VEN combined with IC as induction regimen in patients with de novo FLT3/ITD (+) AML. Secondary purpose was overall survival (OS), event-free survival (EFS), disease-free survival (DFS).

Results

Between January, 2022 and June, 2024, 63 newly diagnosed FLT3-ITD (+) AML patients were enrolled and treated with VEN combined with IC as induction therapy. The median age was 40 years (range, 16-59). The median allelic ratio of FLT3-ITD mutation was 0.53(0.01-14.75). Within this cohort, 28 patients received VEN+DA, 26 patients were treated with VEN+HAA, and 9 patients underwent treatment with VEN+HAD. One patient died during the induction therapy and one patient was not evaluated. The ORR(CR+PR) rate after one cycle of induction was 97.7% (59/61;95% CI 92.3–100%) with CR rate of 91.80% (56/61,95% CI 87.2–99.7%). Moreover, 92.5% (49/53) of the patients achieved CR with undetectable MRD (95% CI 85.1–99.8%). Grade 3 or worse adverse effects included neutropenia (100%), thrombocytopenia (100%), febrile neutropenia (98.4%). The median neutrophil and platelet recovery times were 14(range:5-52) and 14(range:6-63) days, respectively.

Until June,30, 2024, with a median follow-up of 9 (1-25) months, 19.0% of patients underwent allo-HSCT. The median OS, EFS and RFS were not reached. The estimated one-year OS, EFS and RFS were 73% (95% CI: 61.2-84.8%), 59% (95% CI: 45.3-72.7%) and 59% (95% CI: 45.3-72.7%), respectively.

Conclusion

Venetoclax in combination with IC is a highly effective and safe induction therapy for newly diagnosed FLT3-ITD positive AML patients.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH